Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complex (EBNA1 peptide-HLA complex) is a major histocompatibility complex presenting a processed peptide epitope derived from the EBNA1 protein of the Epstein-Barr virus (EBV). EBNA1 is a multifunctional viral protein essential for the replication, segregation, and maintenance of the EBV episome during latent infection, and it is uniquely expressed in all EBV-associated malignancies, including nasopharyngeal carcinoma, Burkitt's lymphoma, Hodgkin's lymphoma, and EBV-positive gastric cancer. Although EBNA1 contains a glycine-alanine repeat (GAr) domain that inhibits its proteasomal degradation and limits classical MHC class I presentation, EBNA1-derived peptides are endogenously processed and presented on both HLA class I (e.g., HLA-A*02:01, HLA-B*35:01) and HLA class II (e.g., HLA-DP5, HLA-DR1) molecules. This complex serves as a highly specific therapeutic target for T-cell receptor-engineered T-cell (TCR-T) therapies (such as YT-E001), TCR-like monoclonal antibodies (such as clone E1), and TCR-like chimeric antigen receptor (CAR) T cells. These immunotherapies recognize the specific peptide-HLA conformation on the surface of EBV-infected or malignant cells, triggering targeted cell lysis via mechanisms like TCR-mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). However, targeting this complex presents challenges, including potential cross-reactivity with self-peptides (such as GlialCAM, which is implicated in the molecular mimicry driving multiple sclerosis), risk of cytokine release syndrome (CRS), and tumor immune evasion through HLA downregulation.
Immunotherapies targeting the EBNA1 peptide-HLA complex act by binding specifically to the presented viral peptide in the groove of the HLA molecule. This binding triggers targeted cell lysis of EBV-infected or malignant cells through T-cell receptor (TCR)-mediated cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or chimeric antigen receptor (CAR)-mediated cytotoxicity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr virus nuclear antigen 1 peptide-human leukocyte antigen complex (EBNA1 peptide-HLA complex).